dm+d

Unassigned

New Medicines

Metastatic pancreatic cancer - in combination with mFolfirinox (oxaliplatin, folinic acid, irinotecan, flurouracil)

Information

New molecular entity
Rafael Pharmaceuticals
Rafael Pharmaceuticals

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Lipoate analog, targeting mitochondrial tricarboxylic acid (TCA) cycle
Pancreatic cancer is the 11th most common cancer in the UK [4]. There are about 10,000 new pancreatic cancer cases every year, which is 28 new cases per day [5].
Metastatic pancreatic cancer - in combination with mFolfirinox (oxaliplatin, folinic acid, irinotecan, flurouracil)
Intravenous infusion